Dose proportionality of iloperidone in patients with schizophrenia.

被引：0
|
作者：
Vaidyanathan, S [1 ]
Barilla, D [1 ]
Choudhury, S [1 ]
Gumbhir-Shah, K [1 ]
Hayes, M [1 ]
Prasad, P [1 ]
Ma, P [1 ]
Sedek, G [1 ]
机构：
[1] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2002年 / 71卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P68 / P68
页数：1
相关论文
共 50 条
  • [1] Iloperidone In Schizophrenia
    Scott, Lesley J.
    CNS DRUGS, 2009, 23 (10) : 867 - 880
  • [2] Iloperidone for schizophrenia
    Rado, Jeffrey
    Janicak, Philip G.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (12) : 2087 - 2093
  • [3] Schizotypy in relatives of patients with schizophrenia.
    Gutierrez Maldonado, Jose
    Caqueo Urizar, Alejandra
    Ferrer Garcia, Marta
    PSICOTHEMA, 2006, 18 (03) : 433 - 438
  • [4] ILOPERIDONE FOR THE TREATMENT OF SCHIZOPHRENIA
    Bishop, J. R.
    Bishop, D. L.
    DRUGS OF TODAY, 2010, 46 (08) : 567 - 579
  • [5] Reduction in olanzapine therapeutic dosage using a subclinical dose of fluvoxamine in patients with schizophrenia.
    Albers, LJ
    Reist, C
    Ozdemir, V
    Marder, S
    Raggi, MA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P84 - P84
  • [6] Iloperidone for the Treatment of Schizophrenia
    Marino, Jehan
    Caballero, Joshua
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (05) : 863 - 870
  • [7] Schizophrenia.
    Remschmidt, H
    ZEITSCHRIFT FUR KINDER-UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE, 2006, 34 (01): : 67 - 67
  • [8] Schizophrenia.
    Wilmanns, K
    ZEITSCHRIFT FUR DIE GESAMTE NEUROLOGIE UND PSYCHIATRIE, 1922, 78 : 325 - 372
  • [9] Sex chromosomal aberrations in patients with schizophrenia.
    Atanasova, S
    Naichova, L
    Michov, V
    Nacheva, M
    Zaharieva, B
    Vazharova, R
    Toncheva, D
    AMERICAN JOURNAL OF MEDICAL GENETICS, 2000, 96 (04): : 553 - 553
  • [10] Population pharmacokinetics of sertindole in patients with schizophrenia.
    Ouellet, D
    Cao, G
    Staser, J
    Granneman, GR
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PII50 - PII50
12345